Is BPC-157 Legal in Arizona? How to Access It Through Legitimate Channels

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a partial sequence of human gastric juice protein BPC. Pre-clinical animal research suggests it may accelerate tendon, muscle, and gastrointestinal tissue repair, but no large-scale randomized controlled trial has confirmed those effects in humans.

Because peptides sit at the intersection of drug law, compounding pharmacy regulation, and sports supplement commerce, the legal question is genuinely complicated. Getting this wrong can expose a patient to counterfeit products, a prescriber to DEA/state board scrutiny, and a pharmacy to FDA enforcement action.

The Core Issue: No FDA Approval

The FDA approves drugs under 21 U.S.C. §355. BPC-157 has never cleared that process. Without an approved New Drug Application (NDA), BPC-157 cannot be legally marketed as a drug in interstate commerce in the United States. The FDA's position is that a substance lacking approval is an unapproved drug if it is intended to diagnose, cure, treat, or prevent a disease in humans. [1]

Why Animal Research Does Not Translate to Legal Human Use

Multiple rodent studies have shown BPC-157 accelerates Achilles tendon healing and reduces gastric ulceration. One frequently cited paper by Sikiric et al. (2018) described significant tendon-to-bone healing in rats. [2] Compelling as those findings are, they carry no regulatory weight in the FDA's human-drug framework. Pre-clinical data supports IND applications; it does not substitute for them.

The FDA's 503A Bulk Substances List: Where BPC-157 Currently Stands

This section contains the most consequential regulatory development for anyone seeking BPC-157 in Arizona or any other state.

What 503A Means for Compounding Pharmacies

Section 503A of the Food, Drug, and Cosmetic Act (FD&C Act) permits licensed pharmacists to prepare patient-specific compounds without an NDA, provided the bulk drug substance meets specific criteria. One criterion is that the substance must appear on the FDA's 503A "Bulks List" (the positive list) or must not be on the negative lists. [3]

The FDA evaluates candidate substances through a public nomination process and sorts them into three categories:

• Category 1: Substances that may be used in 503A compounding (proposed for inclusion on the positive list).
• Category 2: Substances for which the FDA has identified safety or effectiveness concerns, making them inappropriate for 503A compounding.
• Category 3: Substances that need more information before evaluation.

BPC-157's Category 2 Designation

In its 2023 update to the 503A bulk substances evaluation, the FDA placed BPC-157 in Category 2. [4] A Category 2 designation means the agency found that the substance lacks adequate safety and effectiveness data to support its use in compounded preparations for humans. That determination does not carry the same legal force as a final rule banning the compound outright, but it signals FDA's intent to restrict compounding and informs enforcement priorities.

Pharmacies that compound BPC-157 for patients after this designation face elevated inspection risk. Any pharmacy mailing BPC-157 into Arizona from another state is engaged in interstate commerce under heightened scrutiny.

503B Outsourcing Facilities and BPC-157

Section 503B covers outsourcing facilities, which can produce larger batches without patient-specific prescriptions but must comply with Current Good Manufacturing Practice (CGMP) standards. [5] The FDA's 503B bulk substances list does not include BPC-157 either. Outsourcing facilities have the same prohibition on compounding it for human use.

Arizona State Law: What the State Adds (and Does Not Add)

Arizona does not have a statute that explicitly permits or prohibits BPC-157 beyond federal law. The Arizona State Board of Pharmacy (AZBOP) regulates compounding under A.R.S. §32-1901 et seq. And generally defers to FDA guidance on bulk substances. [6]

The Arizona Medical Practice Act

Arizona physicians operate under A.R.S. §32-1401, which governs the practice of medicine. Prescribing or administering an unapproved drug outside the protection of a clinical trial can constitute unprofessional conduct under that statute. No carve-out exists for peptides specifically.

Arizona does permit physician-supervised off-label use of FDA-approved drugs. BPC-157 is not FDA-approved, so that off-label pathway does not apply here.

Is There a "Right to Try" Angle?

Arizona passed a state Right to Try law (A.R.S. §36-1311) mirroring the federal Right to Try Act of 2018. [7] That law applies to terminally ill patients seeking investigational drugs that have completed Phase I trials. BPC-157 has not completed a Phase I trial in the U.S. As a drug product, so the Right to Try pathway is currently closed for BPC-157.

State Controlled Substances Scheduling

BPC-157 does not appear on the Arizona Controlled Substances Scheduling list and is not scheduled federally under the DEA's Controlled Substances Act. Its legal restriction comes from FDA drug approval law, not from scheduling. Patients sometimes conflate these two frameworks. The absence of scheduling does not mean BPC-157 is freely legal for human use.

Research Chemical Sales: The Gray Market Reality

Despite the FDA's Category 2 signal, BPC-157 is widely sold online as a "research chemical" with labels stating "not for human use." Understanding what that label does and does not protect is important.

What "Research Use Only" Actually Means

Vendors selling peptides as research chemicals rely on the premise that selling a substance for in-vitro or animal research does not trigger FDA drug law. That argument has limited durability when the vendor's marketing, customer base, and product format (injectable vials, bacteriostatic water kits) make clear that human use is the actual intended purpose. The FDA has sent warning letters to multiple peptide vendors on exactly this basis. [8]

Risks to Arizona Consumers

A consumer who purchases BPC-157 from an online research chemical vendor for self-injection faces several concrete risks:

1. Contamination: Products are not manufactured under CGMP. A 2020 analysis published in the journal Substance Abuse found that a significant proportion of research peptides purchased online failed purity testing.
2. Mislabeling: The actual concentration may differ from the stated dose.
3. No physician oversight: Dosing errors, injection site infections, and adverse reactions occur without any safety net.
4. Legal exposure: Self-administering an unapproved drug does not carry criminal penalties for the individual under most circumstances, but it removes any medical liability protection.

Legitimate Access Pathways in Arizona (Current Options)

The legal options available to an Arizona resident in 2025 are narrower than most online sources suggest. Here is an honest accounting.

IND-Protected Clinical Trials

The only fully protected pathway for human use of BPC-157 is enrollment in a clinical trial operating under an Investigational New Drug (IND) application approved by the FDA. ClinicalTrials.gov currently lists a small number of studies involving BPC-157 or closely related gastric peptides, though most are observational or conducted outside the U.S. [9] An Arizona patient could theoretically enroll in a qualifying trial if one opens at a site in Arizona or another state.

HealthRX Clinical Access Framework for BPC-157 in Arizona (2025)

| Access Path | Legal Status | Physician Required | Realistic for Most Patients? | |---|---|---|---| | IND clinical trial | Fully protected | Yes (PI) | Rarely, limited sites | | 503A compounding pharmacy | High risk (Category 2) | Yes | Not recommended | | 503B outsourcing facility | Prohibited | N/A | No | | Research chemical vendor | Gray market, FDA scrutiny | No | Not advised for human use | | Importation from abroad | Generally illegal under 21 U.S.C. §381 | No | No | | FDA-approved drug (off-label) | N/A | N/A | BPC-157 not approved |

Working With a Telehealth Physician in Arizona

A telehealth physician licensed in Arizona can evaluate a patient's symptoms, review whether any investigational options apply, and, in principle, write a compound prescription. The pharmacist, however, must decline to fill a prescription for a Category 2 substance under current FDA guidance. A responsible telehealth clinic will be transparent about this barrier rather than directing patients to gray-market compounders.

Monitoring for Regulatory Changes

The FDA's evaluation process is ongoing. The Category 2 designation is not a final rule. If new Phase I or Phase II human safety data emerges, the FDA could re-evaluate BPC-157 for the 503A positive list or a company could file an NDA. Arizona patients and physicians who want to stay current should monitor the FDA's compounding updates page directly. [10]

What the Evidence Actually Shows: Clinical Data Summary

Separating legal status from scientific interest is worth doing. The legal constraints on BPC-157 do not mean the compound lacks biological plausibility. They mean the human safety and efficacy data required by U.S. Drug law have not been produced.

Animal Model Evidence

Sikiric and colleagues have published extensively on BPC-157's effects in rodent models of gastrointestinal injury, tendon repair, and neurological insult. A 2018 paper in the Journal of Physiology and Pharmacology described accelerated tendon-to-bone healing in rats at 10 mcg/kg doses given intraperitoneally. [2] A separate rodent study documented gastroprotective effects comparable to omeprazole in acetic acid-induced ulcer models. [11]

Human Data: Almost Nonexistent

As of 2025, no Phase III randomized controlled trial of BPC-157 in humans has been published in a major peer-reviewed journal. The Cochrane Database of Systematic Reviews does not contain a review specific to BPC-157. One reason the FDA placed BPC-157 in Category 2 is precisely this absence of adequate human safety data. [4]

The FDA's guidance on bulk drug substances for compounding states: "A substance should have a balancing of benefits and risks that supports its use in compounding, taking into account the risks inherent in the substance, the condition to be treated, and the availability of alternative treatments." BPC-157 failed that balance test under current evidence. [3]

What Patients Report Anecdotally

Patient forums and case reports describe uses including tendon injury recovery (commonly 250 mcg to 500 mcg daily, subcutaneous), inflammatory bowel symptom relief, and post-surgical healing acceleration. These accounts are not peer-reviewed evidence. They also reflect doses and routes that have never been validated in controlled human trials.

What Arizona Physicians Need to Know

Physicians in Arizona who receive patient inquiries about BPC-157 are caught between patient demand and a regulatory framework that offers no safe harbor for prescribing it.

Prescribing Liability

The Arizona Medical Board can investigate a physician for prescribing drugs not approved for human use outside a clinical trial context. While a single BPC-157 prescription has not, to public knowledge, resulted in Arizona Medical Board discipline, the risk profile is real. The absence of reported cases reflects the novelty of peptide enforcement, not its absence.

Informed Consent Considerations

If a physician chooses to discuss BPC-157 with a patient, the conversation should include: the drug's unapproved status, the FDA's Category 2 designation, the lack of human Phase II or Phase III trial data, and the absence of a legal compounding pathway. Documenting that conversation in the chart is standard risk management.

Recommending the IND Pathway

Physicians genuinely interested in BPC-157's therapeutic potential for specific patients, such as those with refractory Crohn's disease or severe tendinopathy unresponsive to standard care, can contact FDA's Division of Drug Information to ask about the IND application process for a single-patient compassionate use (expanded access) request. [12] That process is arduous, but it is the legally clean option.

Frequently Asked Questions